Pharmidex

Pharmidex is an AAALAC-accredited, UK-based CRO founded in 2002. We provide high-quality, cost-effective, flexible and rapid solutions in drug metabolism and pharmacokinetics (DMPK), bioanalysis (non-GLP/GLP/GCP), toxicology (non-GLP/GLP), histology, clinical chemistry, hematology, and in vitro ADME. Pharmidex also offers in silico modelling and efficacy models supporting oncology, CNS, respiratory, stroke, autoimmune, and metabolic disease programs. We work with over 250 global clients, including medical charities, academic groups, biotech, and pharma, and have undertaken over 15,000 studies. In addition to our fee-for-service offering, Pharmidex actively seeks collaboration opportunities in grant-funded projects. To date, we have successfully participated in over 30 collaborative grant-funded...

Admet,bioanalysis,toxicology,cns,oncology,metabolite identification,respiratory,gcp/glp bioanalysis,contract research organisation (cro),respiratory,oncology,cns,histology,microdialysis,pharmacokinetics,metabolic disorders,cytokine analysis,aaalac accredited,ecovadis accredited,autoimmune diseases,inflammation,stroke,in silico drug discovery,preclinical models,cell assays,patient sample analysis from clinical trials ,and in vivo therapeutic discovery models

Pharmidex operates in the Research services industry.

Pharmidex's revenue is 11m - 100m

Pharmidex has 11 - 50 employees.